kristoff@GENBANK.BIO.NET (Dave Kristofferson) (12/14/89)
Vol. 18, No. 44, December 15, 1989
NOTICES
NEW RESTRICTIONS ON LOBBYING .............................(84/114)........... 1
Public Health Service
Index: PUBLIC HEALTH SERVICE
REVISED SALARY CEILING FOR RESEARCH CAREER DEVELOPMENT AWARDS ..(117/134).... 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
DATED ANNOUNCEMENTS (RFPs AND RFAs)
CLINICAL RESEARCH CENTERS FOR NEONATAL SEIZURES (RFP) ......(140/180)........ 1
National Institute of Neurological Disorders and Stroke
Index: NEUROLOGICAL DISORDERS, STROKE
DEVELOPMENT OF NONMAMMALIAN MODELS FOR BIOMEDICAL RESEARCH (RFA) ............ 2
Division of Research Resources (183/264, 1204/1404)
Index: RESEARCH RESOURCES
PREVENTION CLINICAL TRIALS UTILIZING INTERMEDIATE ENDPOINTS AND THEIR
MODULATION BY CHEMOPREVENTIVE AGENTS (RFA) ...........(267/343, 1407/2191)... 3
National Cancer Institute
Index: CANCER
ONGOING PROGRAM ANNOUNCEMENTS
SMALL GRANTS PROGRAM FOR BIOETHICS AND CLINICAL DECISION MAKING
RESEARCH .............................................(349/470).............. 4
National Center for Nursing Research
Index: NURSING RESEARCH
INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS AND CAREER DEVELOPMENT
AWARDS IN BIOETHICS AND CLINICAL DECISION MAKING RESEARCH ..(481/580)........ 6
National Center for Nursing Research
Index: NURSING RESEARCH
RESEARCH ON SALIVARY GLANDS AND SECRETIONS .................(583/753)........ 7
National Institute of Dental Research
Index: DENTAL RESEARCH
BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANTS ..(756/969)........ 9
Division of Research Resources
Index: RESEARCH RESOURCES
BIOMEDICAL RESEARCH FELLOWSHIP OPPORTUNITIES ABROAD ........(972/1096)...... 12
John E. Fogarty International Center
Index: FOGARTY INTERNATIONAL CENTER
NIH SMALL INSTRUMENTATION GRANTS PROGRAM ...................(1099/1153)..... 13
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
NOTICES
NEW RESTRICTIONS ON LOBBYING
P.T. 04, 22, 34, 44; K.W. 1014004, 1014006
Public Health Service
On October 23, 1989, the President signed Public Law 101-121, a fiscal year
1990 Appropriations Act for a Federal department, which amends Title 31,
United States Code, by adding a new Section 1352, entitled "Limitation on use
of appropriated funds to influence certain Federal contracting and financial
transactions."
Section 1352 generally prohibits recipients of Federal grants, cooperative
agreements, contracts, or loans from using appropriated funds for lobbying in
connection with the grant, cooperative agreement, contract, or loan. Section
1352 also requires that each person who requests or receives a Federal grant,
cooperative agreement, contract, of $100,000 or more; or a loan, or a Federal
commitment to insure or guarantee a loan, of $150,000 or more, must disclose
lobbying undertaken with nonappropriated funds.
Section 1352 takes effect with respect to Federal grants, cooperative
agreements, contracts, loans, loan insurance commitments, and loan guarantee
commitments that are entered into or made more than 60 days after the date of
enactment of the Act.
Under the legislation, the Office of Management and Budget is instructed to
issue implementing guidance to Federal agencies within 60 days of enactment of
the Act.
Further information on this subject will be provided in the NIH GUIDE as
implementation policies and procedures are developed.
REVISED SALARY CEILING FOR RESEARCH CAREER DEVELOPMENT AWARDS
P.T. 34; K.W. 1014002
National Institutes of Health
The National Institutes of Health announces plans to permit an increase in the
amount of salary that may be requested on a Research Career Development Award
(K04). Beginning with awards made from FY 1990 funds (competing and
non-competing awards made on or after October 1, 1989), requests for base
salaries up to $50,000 per year plus applicable fringe benefits will be
considered.
Proposed salary levels must be in accordance with institutional salary levels,
consistently applied, regardless of the source of support. Justification for
the sum requested must include a comparison of the salaries of other
individuals at the applicant institution of equivalent rank and experience to
that of the awardee.
DATED ANNOUNCEMENTS (RFPs AND RFAs)
CLINICAL RESEARCH CENTERS FOR NEONATAL SEIZURES
RFP AVAILABLE: NIH-NINDS-90-06
P.T. 04; K.W. 0715060, 0403020, 0785035, 0745020, 0755030, 0745027, 0745070
National Institute of Neurological Disorders and Stroke
The National Institute of Neurological Disorders and Stroke, NIH, has a
requirement to establish research centers for the study of neonatal seizures.
The centers are to be established for the purpose of organizing, coordinating
and conducting clinical research concerning the etiology, diagnosis,
treatment, prognosis and prevention of neonatal seizures.
It is anticipated that two awards will be made for a maximum period of four
years each, depending upon the nature and complexity of the research projects
proposed.
Vol. 18, No. 44, December 15, 1989 - Page 1
This is not a Request for Proposals (RFP). The RFP will be issued on or about
December 22, 1989, as a Broad Agency Announcement as defined in FAR Subparts
6.102 (d) (2) and 35.016. A tentative date for receipt of proposals is set
for April 6, 1990.
To receive a copy of the RFP, please submit a written request and two
self-addressed mailing labels to the following address:
Contracting Officer
Contracts Management Branch, DEA
National Institute of Neurological
Disorders and Stroke, NIH
Federal Building, Room 901
7550 Wisconsin Avenue
Bethesda, Maryland 20892
Attn: BAA/RFP No.NIH-NINDS-90-06
All responsible sources may submit a proposal which will be considered by the
NINDS.
DEVELOPMENT OF NONMAMMALIAN MODELS FOR BIOMEDICAL RESEARCH
RFA AVAILABLE: RR-90-01
P.T. 34; K.W. 0755020, 0780015, 0780020
Division of Research Resources
Letter of Intent Receipt Date: February 1, 1990
Application Receipt Date: April 4, 1990
BACKGROUND
The Biological Models and Materials Resources Program (BMMRP) of the Division
of Research Resources (DRR) announces the availability of a Request for
Applications (RFA) for the development of nonmammalian models, in particular,
lower organisms (such as fishes, invertebrates, and microorganisms), in vitro
(cell and tissue culture) systems, and nonbiological models (such as
mathematical and computer simulations) for biomedical research.
Proposals for the study of appropriate invertebrates, lower vertebrates,
microorganisms, cell and tissue culture systems, or mathematical and computer
approaches should be regarded as having the same potential importance to
biomedical research as proposals for work on systems that are phylogenetically
more closely related to humans. Information yielded by such systems can
increase substantially the knowledge of human disease and function.
RESEARCH GOALS AND SCOPE
The overall objective of this RFA is to stimulate research in the development
of appropriate nonmammalian models. The following areas are of particular
interest:
o Research on systems that have the potential of becoming high
connectivity models. High connectivity models are those models
where the body of knowledge about the system is large, and has
resulted in extensive cross information, or connection, with other
systems. An organism that has the potential of becoming a high
connectivity model usually has some information already known about
the system. For example, the metabolism and development of an
organism may be well understood, but other important aspects have
not been explored as fully as possible.
o Research on organisms that are considered high connectivity models.
A few taxa such as E. coli, S. cerevisiae, C. elegans, and D.
melanogaster, have been broadly studied from many points of view.
Applications that explore specific areas to close conspicuous gaps
in information about the model will increase the connectivity of
that system.
o Development of model organisms with special features that have
become useful because the data is readily transferable to humans.
An organism may eventually become a better model or even a high
connectivity model if substantial information on the genetics or
functions of that system are known.
Vol. 18, No. 44, December 15, 1989 - Page 2
o Formulation of mathematical models, in particular when closely
coupled to biological experimentation. There are opportunities for
mathematical modeling in many areas of biomedical research and at
all levels of biological organization.
MECHANISM OF SUPPORT
The support mechanism for this program will be the traditional
investigator-initiated research grant. Support for grants is contingent upon
receipt of appropriated funds. It is anticipated that four to six meritorious
applications will be funded.
Applications should be submitted on Form PHS 398 (Rev. 10/88).
For further information and a copy of the complete RFA, please contact:
Louise E. Ramm, Ph.D.
Acting Director, Biological Models and Materials
Resources Program
Division of Research Resources
Westwood Building, Room 8A07
5333 Westbard Avenue
Bethesda, Maryland 20892
Telephone: (301) 402-0630
PREVENTION CLINICAL TRIALS UTILIZING INTERMEDIATE ENDPOINTS AND THEIR
MODULATION BY CHEMOPREVENTIVE AGENTS
RFA AVAILABLE: 90-CA-02
P.T. 34; K.W. 0715035, 0740018, 0710095, 0760003, 0755015
National Cancer Institute
Application Receipt Date: March 15, 1990
The Division of Cancer Prevention and Control (DCPC), National Cancer
Institute (NCI), invites applications for cooperative agreements to support
clinical trials that are directed toward examining the role of various
chemopreventive agents and/or diet in the prevention of cancer. This is a
follow-up to earlier RFAs that requested grants, and then later, cooperative
agreement proposals in this area.
The major objective of this solicitation is to encourage cancer
chemoprevention clinical trials that utilize biochemical and/or biological
markers to identify populations at risk and/or to provide intermediate
endpoints that may predict later reduction in cancer incidence rates.
These studies may be developed in phases, including a pilot phase, which could
later proceed to a full-scale intervention. The main emphasis should be on
small, efficient studies aimed at improving future research designs of
chemoprevention trials, providing biologic understanding of what is happening
in the trials, or providing better, more quantitative and more efficient
endpoints for these trials. After successful completion of the pilot phase
(i.e. demonstrated modulation of marker endpoints by the intervention),
subsequent studies can include Phase III clinical trials involving the
designated agent, the utilization of the monitoring test system and a cancer
incidence or mortality endpoint.
Investigators may apply at this time for the pilot phase or submit an
application for both phases. However, if the application is for the pilot
phase only, the proposed study must describe its relevance to a clinical
application and utilize a chemopreventive agent, marker test system, and study
population that later could be the subject of a full scale, double-blind,
randomized, risk-reduction clinical trial.
Applicants funded under this RFA will be supported through the cooperative
agreement mechanism. An assistance relationship will exist between NCI and
the awardees to accomplish the purpose of the activity. The recipients will
have primary responsibility for the development and performance of the
activity. However, there will be government involvement with regard to: (1)
assistance securing an Investigational New Drug (IND) approval from the Food
and Drug Administration (FDA); (2) monitoring of safety and toxicity; (3)
coordination and assistance in obtaining the chemopreventive agent; and (4)
quality assurance with regard to the clinical chemistry aspects of the study.
Awards will not be made until all arrangements for obtaining the IND, agent,
and its delivery are completed. Final awards will also consider not only the
Vol. 18, No. 44, December 15, 1989 - Page 3
cost of the clinical trial but also the cost of the agent and its formulation
if necessary.
Applications should include a suitable representation of women and minority
populations of individuals such as those aforementioned. If the applicant
cannot comply, a reasonable explanation should be provided.
This RFA solicitation represents a single competition, with a specified
deadline of March 15, 1990, for receipt of applications. All applications
received in response to the RFA will be reviewed by the same NCI Initial
Review Group (IRG).
To ensure their review, applications should be received by March 15, 1990.
Applications received after that date will not be considered under this RFA.
Inquiries may be directed to:
Marjorie Perloff, M.D.
Chemoprevention Branch
Executive Plaza North, Suite 201
National Cancer Institute
Bethesda, Maryland 20892-4200
Telephone: (301) 496-8563
ONGOING PROGRAM ANNOUNCEMENTS
SMALL GRANTS PROGRAM FOR BIOETHICS AND CLINICAL DECISION MAKING RESEARCH
P.T. 34; K.W. 0783010, 1014004, 0785035, 0785130
National Center for Nursing Research
I. BACKGROUND AND GOALS
The mission of the National Center for Nursing Research (NCNR) is to conduct,
support, and disseminate information respecting basic and clinical nursing
research, research training, and other programs in patient care research. The
National Advisory Council for Nursing Research recognizes the importance of
research in the area of bioethics in clinical practice and has developed a
statement of research in this area which is available from NCNR at the address
below.
NCNR also sponsored an interdisciplinary bioethics workshop as a means of
exploring the research opportunities in bioethics and clinical practice.
Proceedings from the workshop are available from NCNR staff. As a result of
both endeavors, NCNR is issuing this program announcement to encourage
qualified researchers and multidisciplinary research teams to submit
applications for small-scale studies and pilot projects that focus on the
bioethical issues and dilemmas central to clinical decision making that relate
to clinical practice. Submitted studies must be empirically based, include an
interdisciplinary perspective, and examine questions in the clinical settings
where the problem exists. Moreover, it is the National Institutes of Health
and the Alcohol, Drug Abuse, and Mental Health Administration policy that, if
women or minorities are not included in a given study, a clear rationale for
this exclusion must be provided. It is anticipated that findings from pilot
projects, feasibility studies, or small scale studies will provide a basis
from which investigators can build larger studies.
II. MECHANISM OF SUPPORT
As a means of laying the groundwork for bioethics and clinical decision making
research, NCNR announces the Small Grants (R03) Program for Bioethics. The
R03 is a non-renewable award limited to a total of $35,000 in direct costs for
the entire project period. The project period may be up to two years. The
purpose of the R03 is to provide research support for empirically-based
small-scale studies, pilot projects, or feasibility studies in the area of
bioethics and clinical decision making research.
III. ELIGIBILITY
Application to the Small Grants Program (R03) is open to both new and
experienced investigators engaged in clinical research from non-profit
organizations and institutions, state and local governments and their
agencies, and profit-making organizations. Submission of an R03 application
precludes concurrent submission of another research grant application
containing the same research proposal during that particular review cycle.
Vol. 18, No. 44, December 15, 1989 - Page 4
However, applicants may utilize alternative existing mechanisms such as the
R01 or R29 for other bioethical and clinical practice studies.
IV. APPLICATION AND REVIEW PROCEDURES
Applications for the Small Grants Program (R03) should be submitted to the
Division of Research Grants on Application Form PHS 398 (Rev. 10/88) for an
annual August 23 receipt date. The mailing address is as follows:
Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892**
Read GENERAL INFORMATION of the PHS 398, follow the GENERAL INSTRUCTIONS on
pages 1-11 of the application kit, and use SPECIFIC INSTRUCTIONS on pages
12-22, except as indicated below. The entire application should not exceed 20
pages, excluding biographical sketches. Appendices should not be submitted.
Page 12 - Item 2 Check "Yes" and enter Bioethics and Clinical Decision Making.
Page 14 - Item 6 The proposed project period may be up to, but must not
exceed, two years.
Page 14 - Item 8a The amount for the total project period is $35,000 in direct
costs.
Page 19 - Biographical Sketch - Do not exceed one page per biographical
sketch.
Pages 20 through 22 - Follow general instructions.
Page 23 - Appendix - Do not submit an appendix.
V. REVIEW PROCEDURE AND CRITERIA
Applications submitted in response to this announcement will be reviewed in
competition with other applications by an appropriate initial review group in
accord with the usual NIH peer review procedures and criteria. Applications
will be evaluated with respect to the following criteria: the significance
and scientific merit of the proposed project; level of innovation; the
probability that the study will provide a basis for more extended research in
the scientific area; the investigator's background and training for carrying
out the project; and the adequacy and availability of resources and facilities
to carry out the project.
VI. REPORTING REQUIREMENTS
When an award is made in response to a Small Grant (R03) application, an
annual progress report and Financial Status Report must be submitted. Within
90 days after the termination of the award, a Final Progress Report is
required. This final reporting requirement is the same as that for other
types of research grants and is in accord with 42 CFR Part 52 and 45 CFR Part
74. VII. CONSULTATION WITH PROGRAM STAFF
Before preparing the R03 in bioethics and clinical decision making research,
applicants should consult with the NCNR program staff about their proposed
project under this announcement. Applicants should contact:
Dr. Patricia Moritz
Chief, Nursing Systems Branch
National Center for Nursing Research
Building 31, Room 5B09
Bethesda, Maryland 20892
Telephone: (301) 496-0523
This program is described in the Catalog of Federal Domestic Assistance No.
13.361, Nursing Research. Awards are made under the authority of the PHS Act,
Sections 301, 483, 484, and 485, as amended by Public Law 99-158 and 97-219.
Awards are administered under PHS grant policies and Federal regulations 42
CFR Part 52 and 45 Part 74.
Vol. 18, No. 44, December 15, 1989 - Page 5
INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS AND CAREER DEVELOPMENT AWARDS IN
BIOETHICS AND CLINICAL DECISION MAKING RESEARCH
P.T. 22; K.W. 0783010, 1014004, 0785035, 0785130
National Center for Nursing Research
I. Background and Goals
The mission of the National Center for Nursing Research (NCNR) is to conduct,
support, and disseminate information respecting basic and clinical nursing
research and research training in patient care. As clinical practice becomes
more complex, ethical issues related to patient care and clinical decision
making have emerged for patients, families, and health care providers. NCNR
and the National Advisory Council for Nursing Research recognize the
importance of research training in bioethics and clinical decision making and
have developed a statement in this area of research which is available from
NCNR. NCNR also sponsored an interdisciplinary bioethics workshop as a means
of exploring the research opportunities in bioethics and clinical practice.
The need for research training was underscored. Proceedings from the workshop
are available from NCNR staff.
NCNR is issuing this program announcement to invite applicants to compete for
Individual National Research Service Awards (NRSA), including predoctoral,
postdoctoral, and senior fellowships, and Career Development Awards (Clinical
or Academic Investigator Awards) for research training support related to
bioethics in patient care and clinical decision making. NCNR supports
research training programs that emphasize an empirical approach to bioethical
problems, include an interdisciplinary perspective, and encourage the conduct
of studies in the clinical area in which the problems occur. These awards are
available to newly developing investigators as well as to senior scientists
wishing to refocus their research directions.
II. Eligibility
All policies and requirements which normally govern the grant programs of the
Public Health Service apply. Applicants must meet the respective criteria for
the Individual National Research Service Award for predoctoral, postdoctoral,
and senior fellowships or the Clinical Investigator and Academic Investigator
Awards. To obtain application kits and guidelines for NRSAs contact:
Office of Grants Inquiries
Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892
Telephone: (301) 496-7441
Specific NCNR criteria for the NRSAs may be obtained by contacting:
National Center for Nursing Research
Division of Extramural Programs
Building 31, Room 5B09
9000 Rockville Pike
Bethesda, Maryland 20892
Telephone: (301) 496-0523
III. Application Procedures
NRSA applicants should use form PHS 416-1 (Rev. 7/88). Career Development
Award applicants should use PHS 398 (Rev. 10/88). In order to expedite the
application form's routing within NIH, indicate that your proposal is in
response to this program announcement on line 3 of PHS 416-1 face page; and
line 2 of PHS 398 face page. Applications should be submitted to the Division
of Research Grants in accordance with the usual annual receipt dates of
January 10, May 10, and September 10 for NRSAs and February 1, June 1, and
October 1 for Career Development awards. The mailing address is as follows:
Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, Maryland 20892**
IV. Review Procedures and Criteria
Applications in response to this announcement will be reviewed in competition
with other applications and in accord with the usual NIH peer review
procedures and criteria. Applications will be reviewed for scientific and
technical merit by an initial review group; second level review will be by an
appropriate advisory council in the case of the Career Development awards.
Vol. 18, No. 44, December 15, 1989 - Page 6
Second level review of individual fellowship applications will be conducted by
an appropriate Executive Review Group.
Additional information related to NCNR's Academic and Clinical Investigator
Awards can be found in the NIH Guide for Grants and Contracts, Vol. 15, No.
21, October 10, 1986. Interested applicants are encouraged to consult with
NCNR program staff prior to submission:
Dr. Patricia Moritz
Chief, Nursing Systems Branch
National Center for Nursing Research
Building 31, Room 5B09
Bethesda, Maryland 20892
Telephone: (301) 496-0523
This program is described in the Catalog of Federal Domestic Assistance
No.13.361, Nursing Research. Awards are made under the authority of the PHS
Act, Sections 301, 483, 484, 485, and 487 as amended by Public Law 99-158 and
97-219. Awards are administered under PHS grant policies and Federal
regulations 42 CFR Part 52 and 45 CFR Part 74.
RESEARCH ON SALIVARY GLANDS AND SECRETIONS
P.T. 34; K.W. 0715148, 1002034, 0710070, 0765015, 0790000, 0780015
National Institute of Dental Research
PURPOSE
The Salivary Glands and Secretions Program of the Caries, Restorative
Materials, and Salivary Research Branch of the Extramural Program of the
National Institute of Dental Research (NIDR) supports studies to improve
knowledge of the development, structure, function, and diseases of the
salivary glands and to determine the influence of salivary constituents on
oral health. Toward this end, this program seeks to expand its support of
basic and clinical research, research training, and manpower development in
the broad area of the salivary system.
BACKGROUND
Salivary gland research over the past two decades has been compartmentalized
into two general areas: (1) salivary secretions (extracellular events) and
(2) salivary glands (intracellular processes). Our knowledge of salivary
secretions has proceeded at a faster pace than that of intracellular
processes. Nevertheless, salivary research is at a crossroads due to the
emergence of new biologies, most notably recombinant technologies, cell
biology, and protein engineering. Indeed, the future of salivary research
will require the integration of these new disciplines with the more
traditional disciplines. Salivary researchers are at the critical threshold
of having a large volume of scientific information that can be applied
clinically towards enhancing natural defense mechanisms. For example, studies
in the not-too-distant future could be directed toward topical vaccines
against oral disease, the development of artificial salivas, or the diagnostic
use of sialochemistry by dental practitioners. Before these clinical goals
can be achieved, however, additional research is needed regarding the
intracellular and extracellular events that modulate saliva secretion and
function. Finally, clinical applications will demand consideration of normal
vs. the compromised host, normal vs. high-risk populations, and local vs.
systemic diseases in order to develop the appropriate diagnostic and treatment
modalities.
OBJECTIVES AND SCOPE
The NIDR has been a mainstay of support for research and related training on
salivary glands and their secretions and has thus contributed to advances in
basic research and furthered progress in understanding diseases or syndromes
in which salivary gland function is compromised. Based on recommendations by
the Dental Research Programs Advisory Committee at its June 7-8, 1988 meeting,
this program desires to expand its support of research, both basic and
clinical, and research training and career development in the broad area of
this announcement. Accordingly, applications are invited for regular research
project grants (including minority research supplements), program project
grants, FIRST awards, small grants, career development awards, and
postdoctoral fellowships relating but not limited to the following areas:
1. Description of the characteristics of the salivary-associated lymphoid
tissue (SALT) with emphasis on: (a) the mechanisms of homing of immune
Vol. 18, No. 44, December 15, 1989 - Page 7
component cells to and within salivary glands, (b) the cellular elements and
factors regulating differentiation and antibody production within specific
gland types, (c) the intrinsic and extrinsic factors involved in the ontogeny
of salivary immunity, and (d) specific enhancement of host defenses using
local antigen delivery methods.
2. Definition of the molecular mechanisms involved in salivary secretion with
emphasis on the diversity of signal transduction processes present in
different salivary tissues and species.
3. Definition of the mechanisms of salivary-specific gene expression in
developing and adult glands with emphasis on: (a) the trans-acting factors
that modulate gene transcription, and (b) the exogenous factors that modulate
gene expression.
4. Elaboration and definition of the structural basis of salivary molecular
function in health and disease and both in solution and at various tissue and
environmental interfaces, with emphasis on: (a) the development of
appropriate diagnostic reagents to correlate the expression of secreted
salivary products with oral health status, and (b) the application of the
knowledge of structure/function relationships to enhance natural defense
through the development of artificial salivas and modulation of cellular and
secretory gene products.
5. Development and characterization of immortalized normal human and rodent
salivary gland epithelial cell lines with appropriate phenotypic expression.
It should be reemphasized that the above list of potential areas of
investigation is not intended to be either comprehensive or exclusive, nor is
it in order of priority. Rather, it is intended to exemplify the wide variety
of new and/or continuing program emphases.
MECHANISMS OF SUPPORT
Applications considered appropriate responses to this announcement include the
traditional research project grant (R01), the program project grant (P01), the
First Independent Research Support and Transition (FIRST) award (R29), the
small grant (R03), the postdoctoral individual fellowship (F32) and senior
fellowship (F33) awards, and the following career development awards: the
Modified Research Career Development Award (K04), the Physician Scientist for
Dentist Award (K11), and the Individual Dentist Scientist Award (K15). The
specific application forms and kits required in this connection are available
in the business or grants and contracts offices of most academic and research
institutions or may be obtained from:
Office of Grants Inquiries
Division of Research Grants
Westwood Building, Room 449
National Institutes of Health
Bethesda, Maryland 20892-4500
Telephone: (301) 496-7441
APPLICATION AND REVIEW PROCEDURES
Applications will be accepted on an indefinite basis in accordance with the
receipt, Initial Review Group, National Advisory Council, and earliest
possible beginning dates specified in the pertinent application kits.
Applications in response to this announcement will be reviewed on a nationwide
basis in competition with other applications and in accordance with the usual
National Institutes of Health (NIH) peer review procedures. The initial
review for scientific and technical merit will be by an appropriate study
section. Secondary review will be by an appropriate advisory council. The
review criteria will be those customary for the support mechanism selected.
Funding decisions will be based upon relative scientific merit, program
relevance, and the availability of appropriated funds.
The NIH urges applicants to give added attention (where feasible and
appropriate) to the inclusion of women, as well as men, and minorities in the
study populations for all clinical research efforts. Investigators are
reminded that merely including an arbitrary number of such participants in a
given study is insufficient to guarantee generalization of the results. In
attempting to include women and minority groups in a particular study,
attention must be paid to research design and sample size issues. If women
and minorities are not to be included, a clear rationale for their exclusion
should be provided.
Vol. 18, No. 44, December 15, 1989 - Page 8
On the first (face) page, item 2, of the application form PHS 398 (rev.
10/88), the word "Yes" should be checked and the phrase "NIDR P.A.: Research
on Salivary Glands and Secretions" should be typed in the space provided. In
the case of fellowship applications, the same phrase should be typed on line 3
of the face page of form PHS 416-1 (rev. 7/88). With the exception of small
grant applications, which are submitted directly to the NIDR Scientific Review
Branch (Westwood Building, Room 519), the original and six copies of the
application should be sent or delivered to:
Grant Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892-4500**
For further information concerning this announcement and the available
mechanisms of support, applicants are encouraged to contact:
G. G. Roussos, Ph.D.
Chief, Caries, Restorative Materials,
and Salivary Research Branch
National Institute of Dental Research
Westwood Building, Room 505
Bethesda, Maryland 20892-4500
Telephone: (301) 496-7884
This program is described in the Catalog of Federal Domestic Assistance No.
13.121, Diseases of the Teeth and Supporting Tissues. Awards will be made
under authorization of the Public Health Service Act, Title III, Section 301
(Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant
policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This
program is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.
BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANTS
P.T. 18; K.W. 0735000, 1014006
Division of Research Resources
Application Receipt Date: March 26, 1990
BACKGROUND
The Division of Research Resources (DRR) is continuing its competitive
Biomedical Research Support (BRS) Shared Instrumentation Grant (SIG) Program
initiated in Fiscal Year 1982. The program was established in recognition of
the long-standing need in the biomedical research community to cope with rapid
technological advances in instrumentation and the rapid rate of obsolescence
of existing equipment. The objective of the program is to make available, to
institutions with a high concentration of Public Health Service
(PHS)-supported biomedical investigators, research instruments which can only
be justified on a shared-use basis and for which meritorious research projects
are described.
An eligible institution may submit more than one application for different
instrumentation for the March 26, 1990, deadline. However, if multiple
applications are submitted for similar instrumentation from one or more
eligible components of an institution, then documentation from a high
administrative official must be provided, stating that the multiple
applications are a coordinated institutional resource plan, not an unintended
duplication.
RESEARCH GOALS AND SCOPE
This program is designed to meet the special problems of acquisition and
updating of expensive shared-use instruments that are not generally available
through other PHS mechanisms, such as the regular research project, program
project and center grant programs, the Biomedical Research Technology Grant
Program, or the Biomedical Research Support (BRS) Grant Program. Proposals
for the development of new instrumentation will not be considered.
ELIGIBILITY
The BRS Shared Instrumentation Grant Program is a subprogram of the BRS Grant
Program of DRR. Awards are made under the authority of the BRS program and
are made to institutions only, not to individuals. Therefore, eligibility is
Vol. 18, No. 44, December 15, 1989 - Page 9
limited to institutions that receive a BRS grant award. Awards are contingent
on the availability of funds.
MECHANISM OF SUPPORT
BRS Shared Instrumentation Grants provide support for expensive
state-of-the-art instruments utilized in both basic and clinical research.
Applications are limited to instruments that cost at least $100,000 per
instrument or system. The maximum award is $400,000. Types of
instrumentation supported include, but are not limited to nuclear magnetic
resonance systems, electron microscopes, mass spectrometers, protein
sequencer/amino acid analyzers and cell sorters. Support will not be provided
for general purpose equipment or purely instructional equipment. Proposals
for "stand alone" computer systems will only be considered if the instrument
is solely dedicated to the research needs of a broad community of
PHS-supported investigators.
Awards will be made for the direct costs of the acquisition of new, or the
updating of existing, research instruments. The institution must meet those
costs (not covered in the normal purchase price) required to place the
instrumentation in operational order as well as the maintenance, support
personnel and service costs associated with maximum utilization of the
instrument. There is no upper limit on the cost of the instrument but the
maximum award is $400,000. Grants will be awarded for a period of one year
and are not renewable. Supplemental applications will not be accepted. The
program does not provide indirect costs or support for construction or
alterations and renovations. Costs sharing is not required. If the amount of
funds requested does not cover the total cost of the instrument, the
application should describe the proposed sources(s) of funding for the balance
of the cost of the instrument. Documentation of the availability of the
remainder of the funding, signed by an appropriate institutional official,
must be presented to DRR prior to the issuance of an award. Requests for a
multiple instrument purchase totalling over $400,000 must specify and justify
which instrument(s) should be supported within the $400,000 ceiling.
Applicants proposing the direct purchase of an instrument which the
institution has secured or is planning to secure via a lease-purchase
arrangement are strongly encouraged to consult with their institutional
sponsored projects office regarding applicable PHS policy prior to executing
the lease-purchase agreement. Under no circumstances will a SIG application
be accepted for review if the lease-purchase agreement was executed more than
one year prior to submission of the SIG application. Further, the instrument
must be considered state-of-the-art at the time of submission of the SIG
application.
A major user group of three or more investigators should be identified. A
minimum of three major users must have PHS peer-reviewed research support at
the time of the award. The application must show a clear need for the
instrumentation by projects supported by multiple PHS research awards and
demonstrate that these projects will require at least 75 percent of the total
usage of the instrument. Major users can be individual researchers, or a
group of investigators within the same department or from several departments
at the applicant institution. PHS extramural awardees from other institutions
may also be included.
If the major user group does not require total usage of the instrument, access
to the instrument can be made available to other users upon the advice of the
internal advisory committee. These users need not be PHS awardees, but
priority should be given to PHS-supported scientists engaged in biomedical
research.
ADMINISTRATIVE ARRANGEMENTS
Each applicant institution must propose a Principal Investigator who can
assume administrative/scientific oversight responsibility for the
instrumentation requested. An internal advisory committee to assist in this
responsibility should also be utilized. The Principal Investigator and the
advisory group are responsible for the development of guidelines for shared
use of the instrument, for preparation of all reports required by the NIH, for
relocation of the instrument within the grantee institution if the major user
group is significantly altered and for continued support for the maximum
utilization and maintenance of the instrument in the post-award period.
A plan should be proposed for the day-to-day management of the instrument
including designation of a qualified individual to supervise the operation of
the instrument and to provide technical expertise to the users. Specific
plans for sharing arrangements and for monitoring the use of the instrument
should be described.
Vol. 18, No. 44, December 15, 1989 - Page 10
If an award is made, a final progress report will be required that describes
the use of the instrument, lists all users, and indicates the value of the
instrumentation to the research of the major users and to the institution as a
whole. This report is due within 90 days following the end of the project
period.
REVIEW PROCEDURES AND CRITERIA
Applications are reviewed by specially convened initial review groups of the
Division of Research Grants (DRG) for scientific and technical merit and for
program considerations by the National Advisory Research Resources Council
(NARRC) of the DRR. Approximately half of the applications will be reviewed
at the September 1990, NARRC meeting and the remainder at the NARRC meeting in
February 1991. Funding decisions on all applications received for the March
26, 1990, deadline will not be made until the program receives an
appropriation for FY 1991. The Council date will not affect funding
decisions.
Criteria for review of applications include the following:
o The extent to which an award for the specific instrument would meet
the scientific needs and enhance the planned research endeavors of
the major users by providing an instrument that is unavailable or
to which availability is highly limited.
o The availability and commitment of the appropriate technical
expertise within the major user group or the institution for use of
the instrumentation.
o The adequacy of the organizational plan and the internal advisory
committee for administration of the grant including sharing
arrangements for use of the instrument.
o The institution's commitment for continued support of the
utilization and maintenance of the instrument.
o The benefit of the proposed instrument to the overall research
community it will serve.
METHOD OF APPLYING
Copies of specific instructions in completing an application are being mailed
to Program Directors of BRS grants and to sponsored program offices at all
institutions currently receiving BRS grants. Interested investigators should
obtain the application instructions from the Biomedical Research Support
Program Office (301-496-6743) prior to preparing an application.
To identify an application as being in response to this Program Announcement,
check the YES box in item 2 of the application face page and type in
"Biomedical Research Support Shared Instrumentation Grants."
Applications must be received by March 26, 1990. Applications received after
this date will not be accepted for review in this competition. The original
and four copies of the application should be sent to:
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892**
If appendix material is submitted, four collated sets must be included with
the application package. Identify each of the four sets with the name of the
principal investigator and the project title. This material will not be
routinely duplicated and will be used in a limited way by members of the
initial review group.
Two copies of the application and one copy of any appendix material should be
addressed to:
Biomedical Research Support Program
Division of Research Resources
National Institutes of Health
Westwood Building, Room 10A06
5333 Westbard Avenue
Bethesda, Maryland 20892
Vol. 18, No. 44, December 15, 1989 - Page 11
Inquiries should be directed to the Biomedical Research Support Program Office
at (301) 496-6743.
This program is described in the Catalog of Federal Domestic Assistance number
13.337, Biomedical Research Support. Awards will be made under the authority
of the Public Health Service Act, Section 301 (Public Law 78-410, as amended;
42 USC 241) and administered under PHS grant policies and Federal Regulations
42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95
Clearinghouse of Health Systems Agency Review.
BIOMEDICAL RESEARCH FELLOWSHIP OPPORTUNITIES ABROAD
P.T. 22, 26; K.W. 0720005
John E. Fogarty International Center for Advanced Study in the Health Sciences
The John E. Fogarty International Center for the Advanced Study in the Health
Sciences (FIC) of the National Institutes of Health (NIH) announces the
availability of postdoctoral fellowships to U.S. and foreign health scientists
who wish to conduct collaborative research abroad and in the United States,
respectively. The purpose of these fellowships is to enhance the exchange of
research experience and information in the biomedical, behavioral, and health
sciences.
PROGRAMS FOR U.S. SCIENTISTS
SENIOR INTERNATIONAL FELLOWSHIPS. These fellowships offer opportunities to
U.S. biomedical, behavioral, or public health scientists to conduct research
in a foreign institution. The program is for scientists who have established
themselves in their chosen career in the United States and whose professional
stature is well recognized by their peers and institutional officials.
The purpose of this program is to enhance the exchange of ideas and
information about the latest advances in the health sciences, both basic and
clinical, and to permit U.S. scientists to participate abroad in ongoing study
or research in the health sciences.
Fellowships are awarded for a period of 3 to 12 months and provide stipend,
travel, foreign living allowance, and host institutional allowance.
FOREIGN-SUPPORTED FELLOWSHIPS. These fellowships are supported by specific
foreign countries. They provide opportunities for scientists to conduct
collaborative research in the country that provides funding. The maximum
period of support for all programs is 1 year; the minimum period of support
varies with each program.
Participating countries are: Finland, France (CNRS and INSERM), Federal
Republic of Germany, Ireland, Israel, Japan, Norway, Sweden, Switzerland, and
Taiwan.
PROGRAM FOR FOREIGN SCIENTISTS
INTERNATIONAL RESEARCH FELLOWSHIPS. These fellowships offer opportunities to
foreign scientists in the formative stage of their research career to extend
their research experience in U.S. laboratories. Selections are first made by
the Nominating Committee in a participating country or region. Over 50
countries or regions in the Americas, Africa, Asia and the Far East,
Australia, Europe, and New Zealand participate in the program.
The purpose of this program is to forge relationships between distinguished
scientists in the United States and qualified scientists in other countries in
order to solve health-related problems of mutual interest.
Fellowships are awarded for a minimum of 12 months and provide stipend,
travel, and institutional allowance.
PROGRAM FOR EXCHANGE VISITS
HEALTH SCIENTIST EXCHANGES. This program, which supports short-term 2-12
weeks) exchange visits between the United States and Hungary, Poland, Romania,
Yugoslavia, and the Soviet Union, fosters collaborative activities in the
health sciences that are of mutual benefit to the United States and the
participating countries. Priority consideration is given to visits designed
to strengthen or expand on-going collaborative relationships or to explore
prospects for long-term cooperation.
Vol. 18, No. 44, December 15, 1989 - Page 12
BIOMEDICAL RESEARCH EXCHANGES. Awards are made for short-term (2-12 weeks) or
long-term (3-6 months) exchanges of scientists between the United States and
Austria or Bulgaria. The program is limited to support for collaboration in
biomedical research.
Round-trip travel and in-country expenses are provided to participants in the
Health Scientists and Biomedical Research Exchange Programs.
APPLICATION PROCEDURES
Information on eligibility requirements, financial provisions, and award
duration is contained in a brochure on each program, available on request.
Application receipt dates for SENIOR INTERNATIONAL FELLOWSHIPS are January 10,
May 10, and September 10. Application kits are available only from the dean
or equivalent institutional official. Only these persons can request the
application kits from the FIC.
Applications to the HEALTH SCIENTIST AND BIOMEDICAL RESEARCH EXCHANGE
PROGRAMS, THE ALEXANDER VON HUMBOLDT FOUNDATION, AND THE VISITING SCIENTISTS
PROGRAM OF THE NATIONAL SCIENCE COUNCIL, TAIWAN, are accepted throughout the
year. The receipt date for all other foreign-supported fellowships is May 10.
These application kits are available from the FIC between December 1 and April
30.
Prospective applicants for the INTERNATIONAL RESEARCH FELLOWSHIP PROGRAM must
contact the Nominating Committee in their respective countries for information
and application procedures. Application kits are available only through the
Nominating Committees. The Nominating Committees submit their applications to
the FIC annually by August 1.
The NIH is responsible for the scientific review of all applications except
those that are submitted to the Alexander von Humboldt Foundation and the
National Science Council, Taiwan.
INQUIRES
For additional information, send a SELF-ADDRESSED LABEL to the FIC. All
correspondence should indicate clearly the specific program of interest.
Additional information on the Health Scientists and Biomedical Research
Exchange Programs may be obtained from:
International Coordination and Liaison Branch
Fogarty International Center
National Institutes of Health
Building 38A, Room 616
Bethesda, Maryland 20892
Information on all other programs is available from:
International Research and Awards Branch
Fogarty International Center
National Institutes of Health
Building 38A, Room 613A
Bethesda, Maryland 20892